Neutrophil-to-Lymphocyte ratio and Monocyte-to-HDL ratio as a Biomarker of Urolithiasis.

MLA

Butt, Afifa Jamil, et al. “Neutrophil-to-Lymphocyte Ratio and Monocyte-to-HDL Ratio as a Biomarker of Urolithiasis.” Comparative Clinical Pathology, vol. 32, no. 5, Oct. 2023, pp. 783–88. EBSCOhost, https://doi.org/10.1007/s00580-023-03488-9.

APA

Butt, A. J., Khawar, M. B., Afzal, A., Bhalli, A. ullah, Hashmi, M. A. T. S., Afzal, N., Hamid, S. E., Shahzaman, S., Habiba, U., & Shah, S. S. (2023). Neutrophil-to-Lymphocyte ratio and Monocyte-to-HDL ratio as a Biomarker of Urolithiasis. Comparative Clinical Pathology, 32(5), 783–788. https://doi.org/10.1007/s00580-023-03488-9

Chicago

Butt, Afifa Jamil, Muhammad Babar Khawar, Ali Afzal, Asmat ullah Bhalli, Muhammad Abu Talha Safdar Hashmi, Nimra Afzal, Syeda Eisha Hamid, Sara Shahzaman, Ume Habiba, and Syed Shakeel Shah. 2023. “Neutrophil-to-Lymphocyte Ratio and Monocyte-to-HDL Ratio as a Biomarker of Urolithiasis.” Comparative Clinical Pathology 32 (5): 783–88. doi:10.1007/s00580-023-03488-9.